AstraZeneca's imfinzi gets approval in Japan
By Frank Prenesti
Date: Friday 21 Aug 2020
(Sharecast News) - AstraZeneca's Imfinzi has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (SCLC), in combination with etoposide plus a choice of platinum chemotherapy, the company said on Friday.
The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the Phase III CASPIAN trial, showing Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival versus chemotherapy alone, it added.
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly, despite initial response to chemotherapy.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN